Historically, genetic evaluation has been dominated by a clinician-centric traditional model in which a patient’s physician had the central responsibility for testing, such as ordering the test and communicating the results. Conversely, in the direct-to-consumer (DTC) model, consumers are more empowered because they can order their own tests, obtain samples using home test kits, and receive the results directly from the laboratory or company that provides the test. The DTC market has expanded substantially, reigniting controversies over the potential implications of DTC testing for genetic health risks.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. Published online May 30, 2019321(24):2403–2404. doi:10.1001/jama.2019.5670
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: